CORAL GABLES, FL / ACCESSWIRE / February 5, 2019 / The healthcare stock market has been a hotbed of excitement over the course of the past couple of years as companies across the healthcare industry have employed more nuanced approaches to how they offer care to patients. Unlike other industries, healthcare has a unique opportunity, and necessity, of creating innovating products purposed with improving the health/quality of life of consumers. With the advent of new medical technologies and approaches to treating patients suffering from a myriad of diseases, news surrounding innovative companies putting their skills to the test in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC: PHGRF) (CSE: PHGI), Moleculin Biotech Inc (NASDAQ: MBRX), Celldex Therapeutics Inc (NASDAQ: CLDX), and Teladoc Health Inc (NYSE: TDOC) represent four healthcare companies focused on innovating towards the future of healthcare.
Premier Health Group (OTC: PHGRF) (CSE: PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.
The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments meant to showcase to the industry that Premier not only believes in the future of healthcare but is determined to remain ahead of the curve as an innovator leading all others in the sector.
Premier Health Group (OTC: PHGRF) (CSE: PHGI) announced towards the end of last month that, further to its news release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.
Per the official details of the agreement, Premier will pay to the Cloud Practice shareholders total consideration of up to $5 million, $2 million dollars in cash to be paid out as follows: (i) $500,000 paid in cash on signing of the binding LOI as a refundable deposit, (ii) $500,000 in cash payable on closing, (iii) $500,000 in cash payable 90 days after closing, (iv) $500,000 in cash payable within six months of the LOI subject to the satisfaction of certain milestones related to the integration of the Juno EMR, and $3 million payable in common shares of Premier at a deemed price of $0.76 per share.
Dr. Essam Hamza, CEO of Premier Health Group (OTC: PHGRF) (CSE: PHGI), commented, "we are very excited to have completed this acquisition and to have the experienced team at Cloud Practice join the team at Premier Health. With this acquisition, we now have a medical software company with national reach. Thus, enabling us to build on our patient-centric technology platform that will integrate telemedicine, online booking and other premium services with our electronic medical records (EMR) system."
For More Information On Premier Health Group, Click Here
Moleculin Biotech Inc (MBRX), a clinical-stage pharmaceutical company focused on the development of oncology treatments, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Status for its drug candidate WP1066 for the treatment of glioblastoma, the most aggressive form of brain tumor.
Following the Company's announcement, Walter Klemp, Moleculin's Chairman, and CEO, commented, "we continue to be encouraged by the progress of the physician-led clinical trial of WP1066 and, now having the FDA grant Orphan Drug status for WP1066 positions us well for potential marketing of this drug. We believe that WP1066 represents a new class of drugs which we call 'Immune/Transduction Modulators' because it has demonstrated the ability in preclinical testing in animals to both stimulate a natural immune response to tumors and directly attack tumor cells by inhibiting multiple key oncogenic transcription factors, including STAT3, HIF1-α, and c-Myc."
For More Information On Moleculin Biotech Inc, Click Here
Celldex Therapeutics Inc (CLDX) has seen impressive gains in the market this week, as the Company closed Monday's trading session with its shares up 19.35%, trading at $0.69 per share after the closing bell. In early November 2018, the Company announced results it had received from a Phase 1 dose-escalation study of CDX-1140, a fully human agonist anti-CD40 antibody. CD40, expressed on dendritic cells and other antigen presenting cells, has long been an important target for immunotherapy, as it plays a critical role in the activation of innate and adaptive immune responses.
At the time, Tibor Keler, Chief Scientific Officer of Celldex, stated that "we have completed four of the potential eight monotherapy dose levels and, to date, CDX-1140 has been well tolerated. Importantly, we are observing dose-dependent biological effects consistent with CD40-mediated immune cell activity."
For More Information on Celldex Therapeutics Inc, Click Here
Teladoc Health Inc (TDOC), a global leader in virtual care solutions, today announced new capabilities that enable health systems to deliver a broader spectrum of virtual care services and to streamline diagnostic testing orders. According to data presented in the announcement, roughly three-quarters of healthcare systems either currently have or are implementing consumer telehealth programs in 2019 and an increasing number of systems are deploying virtual care to serve complex care needs.
Alan Roga, president, Hospitals and Health Systems, Teladoc Health, said, "virtual care is fundamental to care expansion, clinician efficiency, cost reduction, and quality enhancement across all patient populations. We're thrilled to help our clients evolve their traditional bricks-and-mortar model through continued innovation that naturally extends their infrastructure to meet more patient care needs."
For More Information On Teladoc Health Inc, Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
Contact Information:
SOURCE: StockPrice.com